Since its establishment in 2014, Swixx has become the largest and fastest-growing commercial platform for multinational companies looking to operate indirectly in non-core markets of CEE and Eurasia, including Russia. We have been recognized as a trusted, highly ethical, and loyal partner. Swixx fully replicates our Partners’ business structures and allows our Partners to focus on their priorities, while taking over medical, commercial, regulatory and distribution activities.
Our partners demand best-practice governance. At Swixx we embrace a culture of rigorous corporate governance, highly ethical compliance standards, meticulous quality assurance, and dedication to ensuring patient access to our partner’s portfolio. Our commitment to these principles is reflected in our regular internal and external audits, as well as our status as the only commercial platform with an ISO 37001 Anti-bribery management system. We consider business ethics the core of our culture, and we strive to maintain simple, adaptable business practices that are rational, logical, and transparent. Our patient-centric approach is focused on providing our partners with best-in-class services to meet their specific needs.
Swixx teams are fueled by passionate and dynamic culture, which has made us the top-of-mind choice when our partners think of outsourcing model. Swixx impressive track record at the country level translates to unmatched excellence in ensuring access to innovative medicines for patients and the ability to launch new products.
Swixx is a full-service provider that mirrors the local capabilities of biopharma companies (with the exception of R&D and manufacturing). Our team of experienced pharmaceutical professionals has a deep understanding of the needs of these companies, simplifying operations for our partners by offering a comprehensive set of services that support fast market penetration, patients access and revenue generation, in a compliant and ethical fashion.
At Swixx, we bring added value to our partners by utilizing our demonstrated expertise in market access to establish and enhance patient access. We offer full service and support for price filings and renewals, compilation of reimbursement dossiers, localization of pharmacoeconomic models, and pricing and reimbursement negotiations. Our services are fully aligned with our partners’ strategies.
At Swixx, our headquarter commercial teams and in-country dedicated Business units are committed to ensuring smooth and coordinated transfer of partners’ brand strategy across all markets. Our professionals have a strong track record of designing high-value medico-marketing activities, growing omnichannel customer engagement capabilities, and implementing established sales force effectiveness (SFE) processes. This enables us to effectively execute our partner’s aligned strategy, tailored to meet the unique regional and local needs of each market.
Swixx is actively expanding into new therapeutic areas that are highly science-driven, including recently established fields. Our experienced medical professionals at headquarters, regional and country level possess a deep understanding of this dynamic environment. We maintain close cooperation with professional societies, health authorities, top experts and health care professionals to gather valuable insights during scientific exchange, supporting our partners’ medical strategies and addressing specific medical needs. Our medical teams work closely with Patient Advocacy and Public Affairs to enable successful interaction with patient advocacy groups and ensure a patient-centric approach in real-world practice. Additionally, Swixx’s Medical trainers can provide continuous training and education on disease areas and product knowledge to broader teams, if agreed upon.
With rich experience in managing unregistered products in markets where permissible, including Russia and Eurasian countries, Swixx’s medical staff leads programs to ensure patient access to innovative medicines within Compassionate Use or Named Patient Access settings. Our medical team also performs activities directed to timely diagnosis of several diseases.
Swixx Medinfo service is committed to responding to healthcare professionals’ and patients’ enquiries with the highest level of medical accuracy in alignment with regulatory, legal, and ethical standards. We tailor our responses to meet our partners' specific requirements, ensuring that each enquiry is addressed in line with up-to-date available information in a precise and efficient manner.
At Swixx, our regulatory experts are fully committed to ensuring that life-changing innovative therapies are available for patients and health care providers in our region. They possess a deep understanding of the intricate regulatory requirements and a strong sense of urgency to make these therapies accessible. Our processes of registration and maintenance are in full compliance with regional and local legislation for all the products we handle. At Swixx we strive for regulatory excellence throughout the entire lifecycle of each product, and our rapid and efficient working practices ensure the satisfaction of our partners.
Swixx provides local PV services across our countries under a unified governance model, consolidating country-level operations into a seamless, integrated corporate PV system. This allows us to offer our partners a single interface for oversight and compliance monitoring, ensuring consistent service and outputs globally.
Given diverse local regulatory requirements, our PV teams help our partners as Marketing Authorization Holders to secure local PV systems with a team of Local Persons for Pharmacovigilance (LPPVs) responsible for continuous local PV management across Europe (EU/Non-EU), Russia and Eurasian countries.
Our pharmacovigilance processes are compliant with Marketing Authorization Holders’ pharmacovigilance system. Swixx’ PV team contributes to maintaining a Pharmacovigilance System Master File, provides a complete QPPV office or any part of it, and helps to fulfill all pharmacovigilance obligations across Swixx territories.
Commitment to uncompromised quality is one of the pillars of Swixx’s business strategy.
Quality and responsibility towards all those who use our products and services is a fundamental component of our corporate strategy. We thereby take account of the great significance of quality in product safety in the health care market. Overall, we align the quality policy and Quality Management System throughout the Group to meet criteria that at least fulfill the strict legal requirements for pharmaceutical and health care products.
Comprehensive Quality Management System has been established to ensure compliance with all requirements of EU GDP, EU GMP, EUGVP, ISO 9001 standard and local regulation Competent local and international institutions regularly conduct audits in Swixx BioPharma Company, reporting results that prove our business ambition to exceed quality efficacy.
Swixx AG, Swixx Slovenia, Czech Republic, Bulgaria, Russia, Kazakhstan, and Amicus Serbia possess relevant Wholesale licenses issued by relevant Competent Authority. Main distribution center in Ljubljana also possesses a GMP license for secondary packing activities.
At Swixx we possess exceptional Supply Chain capabilities that enable us to effectively serve both current and future partners. Our logistic center is located in Ljubljana, Slovenia, from where we are supplying all our countries. This includes road transportation of ambient and cold chain (2° - 8°C) products. Our partners’ products (medicines including narcotics, medical devices as well as food supplements) are shipped from Ljubljana to local wholesalers or end-users. Swixx also runs local warehouses in Bulgaria, Czech Republic, Kazakhstan Romania, Russia and Serbia. Additionally, in Ljubljana, we have expandable storage capacity and GMP-licensed secondary packaging facilities.
To meet the needs and to provide the best-in-class service to our Partners, with the assistance of independent experts, we have initiated an anonymous Swixx Partner Satisfaction research to obtain a genuine and objective feedback about the quality of support and areas for improving the level of service that our company is providing to its partners.
Click on the video below to see main research results.
“We are working with Swixx Biopharma in 11 Central Eastern Europe countries and appreciate the strong collaboration, alignment and focus on maximizing patient access and our mutual business opportunities in this important region.”
Thomas Dusink, Head of Partner Markets, International, Seagen
“Swixx is a company which delivers access to treatment and innovation where for a reason the innovative company cannot. They are very good in delivering results with this model because of their expertise, but also because they would like to improve all the time.”
Konstantin Ruichev, Head of PME Hub Specialty Care, Sanofi
“We find Swixx easy to work with, accessible, knowledgeable, willing to grow together and deliver good results.”
Andrew Hardwick, Global Head of Alliances and Partnerships, Sanofi
"Jazz highly values its partnership with Swixx, in particular the team’s dedication, passion and drive for results, combined with their local expertise and entrepreneurial thinking. Swixx and Jazz share the same values when it comes to improving patients’ lives."
Duncan Ferguson, Head of Partner Markets, International & Partner Markets, Jazz Pharmaceuticals
All testimonials have been authorized by individuals and Partners.
Swixx Biopharma SA
Phone: +41 41 5523 440
E-mail: info@swixxbiopharma.com
Address: Neuhofstrasse 5A, CH-6340 Baar
Switzerland
Phone: +420 242 434 242
E-mail: info@swixxbiopharma.com
Address: Hybernská 5 11000 Praha 1
Czech Republic